Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrepopag for platelet reconstruction after hematopoietic stem cell transplantation
ChiCTR2200060057Phase 3Not yet recruiting
- Sponsor
- Zigong First People's Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hetrombopag in Thrombocytopenia (2 arms), sponsored by Zigong First People's Hospital. Primary endpoint: Time to platelet count thresholds after platelet engraftment. Planned start May 2022; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2200060057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060057.